Patents by Inventor Morten A. Karsdal
Morten A. Karsdal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250020653Abstract: Described herein are methods of immunoassay for detecting and/or monitoring cancer in a patient. A sample from the patient is contacted with denatured type III collagen. The amount of binding between the denatured type III collagen and antibodies in the sample that specifically recognise and bind to denatured type III collagen is then detected and determined, and the amount of binding is correlated with values associated with normal healthy subjects, and/or with values associated with known disease severity, and/or with values obtained from the patient at a previous time point, and/or with a predetermined cut-off value.Type: ApplicationFiled: November 8, 2022Publication date: January 16, 2025Applicant: Nordic Bioscience A/SInventors: Nicolas Willumsen, Anne-Christine Anne-Christine, Morten Karsdal
-
Publication number: 20250012810Abstract: A method of immunoassay for detecting in a biological sample a fragment of collagen type VII alpha 1 comprising an N- or C-terminal neo-epitope, the method comprising contacting the biological sample comprising the fragment of collagen type VII alpha 1 comprising the N- or C-terminal neo-epitope with an antibody of the invention, and determining the amount of binding of the antibodyType: ApplicationFiled: July 5, 2024Publication date: January 9, 2025Applicant: NORDIC BIOSCIENCE A/SInventors: Jannie Marie Bülow SAND, Diana Julie LEEMING, Morten KARSDAL
-
Publication number: 20240011997Abstract: Described herein are monoclonal antibodies, assay kits and immumoassay methods for quantifying elastin fragments with a C-terminus amino acid sequence LPGGYGLPYT (SEQ ID NO: 1) in a patient biofluid sample, and uses thereof for detecting or quantifying fibrotic diseases such as chronic obstructive lung disease (COPD).Type: ApplicationFiled: July 25, 2023Publication date: January 11, 2024Applicant: Nordic Bioscience A/SInventors: Karoline Natasja Stæhr Gudmann, Jannie Marie Bülow Sand, Tina Manon-Jensen, Diana Julie Leeming, Morten Karsdal
-
Publication number: 20230340092Abstract: The present invention relates to an antibody, wherein the antibody is specifically reactive with short isoform collagen type XVIII, but does not react with intermediate isoform collagen type XVIII or with long isoform collagen type XVIII. The invention also relates to the use of the antibody in a method of immunoassay for detecting or quantitating short isoform collagen type XVIII, wherein the method may be used to evaluate haemophilic disease.Type: ApplicationFiled: December 22, 2022Publication date: October 26, 2023Applicant: Nordic Bioscience A/SInventors: Tina Manon-Jensen, Morten Karsdal
-
Publication number: 20230258659Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. It relates more particularly to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used as biomarkers for the diagnosis, pre-treatment of patients and during therapy of cartilage disorders. The invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment or during the treatment. It could be used for selecting/identifying subjects to be treated according to specific doses and/or dosing regimens by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk-benefit ratio in subjects.Type: ApplicationFiled: September 1, 2022Publication date: August 17, 2023Applicant: MERCK PATENT GMBHInventors: Christoph H. LADEL, Hans GUEHRING, Anne-Christine BAY-JENSEN, Morten KARSDAL, Per QVIST
-
Publication number: 20230258658Abstract: Disclosed herein are immunoassays, in particular immunoassays for detecting and/or monitoring cardiovascular disease, such as heart failure. Also disclosed are monoclonal antibodies and kits for use in said assays. The assays, antibodies and kits target a C-terminal epitope of type XXVIII collagen.Type: ApplicationFiled: September 3, 2020Publication date: August 17, 2023Applicant: Nordic Bioscience A/SInventors: Shu Sun, Alexander Lynge Reese-Petersen, Federica Genovese, Morten Karsdal
-
Publication number: 20230251271Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. The present invention more particularly relates to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used for the diagnosis and treatment of cartilage disorders. The invention further discloses specific proteins that are related to cartilage response to an FGF-18 compound treatment as well as diagnostic tools and kits based on their expression profile. Thus, the invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment with FGF-18 or during the treatment. It could be used for selecting/identifying subjects to be treated by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk in subjects.Type: ApplicationFiled: September 7, 2022Publication date: August 10, 2023Applicant: MERCK PATENT GMBHInventors: Christoph H. LADEL, Hans GUEHRING, Anne-Christine BAY-JENSEN, Morten KARSDAL, Per QVIST
-
Publication number: 20230152323Abstract: The present invention relates to an assay for detecting secreted proteome acidic and rich in cysteine (SPARC), and more specifically to its use in evaluating lung cancer.Type: ApplicationFiled: September 8, 2022Publication date: May 18, 2023Applicant: Nordic Bioscience A/SInventors: Stephanie Nina Kehlet, Diana Øersnes-Leeming, Morten Karsdal
-
Publication number: 20230052142Abstract: The present invention relates to an assay for detecting Tumstatin, and its use in evaluating lung cancers, such as non-small cell lung cancer (NSCLC), chronic kidney disease (CKD), such as CKD resulting from diabetes, lupus nephritis (LN) and systemic lupus erythematosus (SLE).Type: ApplicationFiled: September 18, 2022Publication date: February 16, 2023Applicant: Nordic Bioscience A/SInventors: Signe Holm Nielsen, Morten Karsdal, Federica Genovese
-
Publication number: 20230030529Abstract: An assay measuring protease mediated degradation of type IV collagen and its biomarker potential for identifying cancer patients with a T-cell permissive tumor microenvironment is described.Type: ApplicationFiled: December 3, 2020Publication date: February 2, 2023Applicant: Nordic Bioscience A/SInventors: Nicholas Willumsen, Christine Jensen, Morten A. Karsdal
-
Patent number: 11531028Abstract: An antibody specifically reactive with an epitope of collagen type X alpha 1 comprised in the NC1 domain C-terminal amino acid sequence SFSGFLVAPM-COOH (SEQ ID NO: 1), and a method of immunoassay for detecting in a biological sample an epitope in the NC1 domain C-terminal amino acid sequence SFSGFLVAPM-COOH (SEQ ID NO: 1) of collagen type X alpha 1, by contacting the biological sample with the antibody, and determining the amount of binding of the antibody.Type: GrantFiled: February 1, 2020Date of Patent: December 20, 2022Assignee: Nordic Bioscience A/SInventors: Anne Christine Bay-Jensen, Yi He, Morten Karsdal
-
Patent number: 11513128Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. The present invention more particularly relates to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used for the diagnosis and treatment of cartilage disorders. The invention further discloses specific proteins that are related to cartilage response to an FGF-18 compound treatment as well as diagnostic tools and kits based on their expression profile. Thus, the invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment with FGF-18 or during the treatment. It could be used for selecting/identifying subjects to be treated by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk in subjects.Type: GrantFiled: September 28, 2018Date of Patent: November 29, 2022Assignee: MERCK PATENT GMBHInventors: Christoph H. Ladel, Hans Guehring, Anne-Christine Bay-Jensen, Morten Karsdal, Per Qvist
-
Patent number: 11467169Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. It relates more particularly to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used as biomarkers for the diagnosis, pre-treatment of patients and during therapy of cartilage disorders. The invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment or during the treatment. It could be used for selecting/identifying subjects to be treated according to specific doses and/or dosing regimens by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk-benefit ratio in subjects.Type: GrantFiled: September 28, 2018Date of Patent: October 11, 2022Assignee: MERCK PATENT GMBHInventors: Christoph H. Ladel, Hans Guehring, Anne-Christine Bay-Jensen, Morten Karsdal, Per Qvist
-
Publication number: 20220317133Abstract: A method of immunoassay for detecting and/or monitoring a cardiovascular disease in a patient and/or assessing the likelihood of or the severity of a cardiovascular disease in a patient, comprising contacting a biofluid sample from a patient with a monoclonal antibody that specifically binds to a C-terminal epitope of the C5 domain of the ?3 chain of type VI collagen, and/or contacting a biofluid sample from the patient with a monoclonal antibody that specifically binds to a C-terminal neo-epitope of the N-terminal propeptide of type III collagen.Type: ApplicationFiled: June 5, 2020Publication date: October 6, 2022Applicants: Nordic Bioscience A/S, Bristol-Myers Squibb Company, The Trustees of the University of PennsylvaniaInventors: Federica Genovese, Morten Karsdal, Lei Zhao, David Gordon, Zhaoqing Wang, Julio Alonso Chirinos Medina
-
Publication number: 20220227848Abstract: The present invention provides monoclonal antibodies that target collagen type XXIII, and to immunoassays and kits employing the antibodies for detecting and quantifying the epitope. The invention also provides a method for identifying and monitoring subjects with inflammatory bowel disease.Type: ApplicationFiled: February 7, 2019Publication date: July 21, 2022Applicant: Nordic Bioscience A/SInventors: Tina Manon-Jensen, Shu Sun, Joachim Høg Mortensen, Morten Karsdal
-
Publication number: 20220146528Abstract: Provided herein is an antibody specifically reactive with an N-terminus neo-epitope of collagen type X alpha 1 in the amino acid sequence H2N-GIATKGLNGP, and its use in an immunoassay for evaluating a disease associated with collagen type X alpha 1, such as osteoarthritis.Type: ApplicationFiled: January 26, 2022Publication date: May 12, 2022Applicant: Nordic Bioscience A/SInventors: Yi He, Anne-Cecilie Bay-Jensen, Morten Karsdal
-
Publication number: 20220047674Abstract: The present invention relates to pharmacogenetics, more specifically to strategies involving biomarkers associated with the clinical response to a compound before or during treatment of a cartilage disorder, such as osteoarthritis. The present invention more particularly relates to the combination of JSW measurements and level of specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used in strategies such as patients' enrichment in clinical trials, patients' selection strategy before or during treatment or for adapting the treatment of a patient in the frame of treatments for cartilage disorder, such as osteoarthritis.Type: ApplicationFiled: September 9, 2019Publication date: February 17, 2022Inventors: CHRISTOPH H. LADEL, HANS GUEHRING, ANNE-CHRISTINE BAY-JENSEN, MORTEN KARSDAL, PER QVIST
-
Publication number: 20210293828Abstract: A method of immunoassay for detecting in a biological sample a fragment of collagen type VII alpha 1 comprising an N- or C-terminal neo-epitope, the method comprising contacting the biological sample comprising the fragment of collagen type VII alpha 1 comprising the N- or C-terminal neo-epitope with an antibody of the invention, and determining the amount of binding of the antibodyType: ApplicationFiled: June 4, 2021Publication date: September 23, 2021Applicant: NORDIC BIOSCIENCE A/SInventors: Jannie Marie Bülow SAND, Diana Julie LEEMING, Morten KARSDAL
-
Publication number: 20210231680Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. It relates more particularly to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used as biomarkers for the diagnosis, pre-treatment of patients and during therapy of cartilage disorders. The invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment or during the treatment. It could be used for selecting/identifying subjects to be treated according to specific doses and/or dosing regimens by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk-benefit ratio in subjects.Type: ApplicationFiled: September 28, 2018Publication date: July 29, 2021Inventors: CHRISTOPH H. LADEL, HANS GUEHRING, ANNE-CHRISTINE BAY-JENSEN, MORTEN KARSDAL, PER QVIST
-
Publication number: 20210231681Abstract: The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. The present invention more particularly relates to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used for the diagnosis and treatment of cartilage disorders. The invention further discloses specific proteins that are related to cartilage response to an FGF-18 compound treatment as well as diagnostic tools and kits based on their expression profile. Thus, the invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment with FGF-18 or during the treatment. It could be used for selecting/identifying subjects to be treated by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk in subjects.Type: ApplicationFiled: September 28, 2018Publication date: July 29, 2021Inventors: CHRISTOPH H. LADEL, HANS GUEHRING, ANNE-CHRISTINE BAY-JENSEN, MORTEN KARSDAL, PER QVIST